Francis Averill

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

William W. Busse, Eugene R. Bleecker, J Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 311 citations

Pharmacy, Pharmacology, Pharmacotherapy +6

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

Tim Harrison, Pascal Chanez, Francesco Menzella et al. · The Lancet Respiratory Medicine · 2020 · 175 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +15

Antigen-induced generation of lyso-phospholipids in human airways.

Floyd H. Chilton, Francis Averill, Walter C. Hubbard et al. · The Journal of Experimental Medicine · 1996 · 131 citations · Full text

Life Sciences, Biochemistry, Immunology +13

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis

Toby M. Maher, Paul Ford, Kevin M. Brown et al. · JAMA · 2023 · 127 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

Toby M. Maher, Susanne Stowasser, Yasuhiko Nishioka et al. · The Lancet Respiratory Medicine · 2019 · 104 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16